Ligand for the neu gene product
CA 2079585 C · Owner: The Trustees Of The University Of Pennsylvania · Inventors: Greene, Mark I.; Davis, James G.; Dobashi, Kunio
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A purified proteinaceous substance bindable with p185 the translation product of the neu oncogene is dislcosed. The purified proteinaceous substance may be characterized in that it increases the activity of the tyrosine kinase contained in the neu oncogene product but does not increase the activity of tyrosine kinase of epidermal growth factor receptor; induces p185 dimerization and internalization; affects the growth of cells which express p185 in a dose dependent manner; is heat stable from about 56 °C to about 100 °C; is degradable by protease; and has a molecular weight of from about 7,000 to about 14,000 daltons in its smallest active form as determined by gel filtration and …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 4, 1991 and granted January 7, 1997. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 4, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 4, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.